Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Rohto Pharmaceutical Co ( (JP:4527) ) has provided an update.
Rohto Pharmaceutical Co., Ltd. announced the issuance of Zero Coupon Convertible Bonds due 2032 to secure low-cost funding amidst rising interest rates. The proceeds, approximately ¥25 billion, will be used to strengthen research and development in core and expansion areas, repay borrowings, and repurchase shares, aiming to enhance profitability and enterprise value while maintaining financial stability.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on over-the-counter (OTC) drugs and skincare products. The company is expanding into new business domains such as regenerative medicine and contract development and manufacturing (CDMO), with a strong emphasis on research and product development.
YTD Price Performance: -14.49%
Average Trading Volume: 5,490
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.54B
For a thorough assessment of 4527 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue